International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy?

Putora, Paul Martin; Leskow, Pawel; McDonald, Fiona; Batchelor, Tim; Evison, Matthiew (2020). International guidelines on stage III N2 nonsmall cell lung cancer: surgery or radiotherapy? ERJ Open Research, 6(1), 00159-2019. European Respiratory Society 10.1183/23120541.00159-2019

[img]
Preview
Text
00159-2019.full.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (483kB) | Preview

Stage III N2 nonsmall cell lung cancer (NSCLC) is a complex disease with poor treatment outcomes. For patients in whom the disease is considered technically resectable, the main treatment options include surgery (with neoadjuvant or adjuvant chemotherapy/neoadjuvant chemoradiotherapy (CRT)) or CRT followed by adjuvant immunotherapy (dependent on programmed death ligand 1 status). As there is no clear evidence demonstrating a survival benefit between these options, patient preference plays an important role. A lack of a consensus definition of resectability of N2 disease adds to the complexity of the decision-making process. We compared 10 international guidelines on the treatment of NSCLC to investigate the recommendations on preoperatively diagnosed stage III N2 NSCLC. This comparison simplified the treatment paths to multimodal therapy based on surgery or radiotherapy (RT). We analysed factors relevant to decision-making within these guidelines. Overall, for nonbulky mediastinal lymph node involvement there was no clear preference between surgery and CRT. With increasing extent of mediastinal nodal disease, a tendency towards multimodal treatment based on RT was identified. In multiple scenarios, surgery or RT-based treatments are feasible and patient involvement in decision-making is critical.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Haematology, Oncology, Infectious Diseases, Laboratory Medicine and Hospital Pharmacy (DOLS) > Clinic of Radiation Oncology

UniBE Contributor:

Putora, Paul Martin

Subjects:

600 Technology > 610 Medicine & health

ISSN:

2312-0541

Publisher:

European Respiratory Society

Language:

English

Submitter:

Beatrice Scheidegger

Date Deposited:

10 Mar 2020 15:09

Last Modified:

07 Jan 2024 01:30

Publisher DOI:

10.1183/23120541.00159-2019

PubMed ID:

32083114

BORIS DOI:

10.7892/boris.141330

URI:

https://boris.unibe.ch/id/eprint/141330

Actions (login required)

Edit item Edit item
Provide Feedback